skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hello, I would like to purchase has some more of these shares but am worried about the potential of the USA cross border tax and especially in the health care field. Do you believe CRH would be included in this tax and should I hold off and see what happens and how will I be able to tell when or if the tax will be imposed? Thanks for your insight.

Read Answer Asked by rick on February 10, 2017
Q: Hi ,if you can clarify a scenario
- Using the finaning done by CVM.v as an example . They raised $12 million at .33 with a 1/2 warrant (full warrant exercise price .70 for 18 months)
The share price was at around .45 yesterday and gapped up to the .55 area today
What are the most likley reasons the share price goes up on this news?
Is it possible they drive it up to short (covering with their .33 cent shares) or is it just a positive reaction to funding
Thanks and excuse any ignorance
David
Read Answer Asked by David on February 08, 2017
Q: I realize that I have a poor understanding of how to value "pre-sales" biotech companies such as TR. How is a quantitative value placed on them - I assume it is based somehow on the potential market share of the company in the specific area they are developing drugs for, as well as the size of that market and the risk of getting product to commercial trade. But this seems all very subjective. For example, TRIL has traded all over the map, the value can seem to double or be cut in half based on some combination of risk profile vs. potential. For the average retail investor, how does one go about trying to value these companies, or is is better to wait until sales start to happen and then try to value to company on sales projection? Other examples could be PLI, or one I'm still trying to forget from years past, ISA. I'm wondering if these types of companies have a place in a responsible portfolio even one is "high growth" oriented?
Read Answer Asked by Kel on February 06, 2017
Q: Hi folks,almost to embaressed to admit still own some Concordia,but company issued n/r:Concordia International Corp. Makes Final Earn Out Payment to Cinven,Today's payment of £72 million, plus interest of approximately £1.5 million, was paid with cash on hand.But a poster stated,"Had to raise 9.5% 1st lien bonds to pay the earn out. Hardly a good sign.". Could I please get your opinion on todays news and future of company going forward, at least Trump yesterday seemed to throw an olive branch at pharma companies that he would work with them and not bury them. Thanks as always, jb
Read Answer Asked by John on February 02, 2017
Q: Hi Peter! SIS said in their statement "There are over a thousand resellers of accessibility products in North America." Their purpose behind this statement was to iterate that there are many opportunities for acquisitions that could improve synergies, but I'm more concerned about how they maintain a competitive advantage. Do they depend too much on R&D? If not, what makes them stand out from the rest and what are the barriers to entry? Is there any brand loyalty among its customers? Do you see them being bought out in the future (i.e. like United Technologies that own OTIS elevators)? Thanks!
Read Answer Asked by Michael on January 23, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!